Provenge Panel's Uncertainty Was More Persuasive To FDA Than Its Vote
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA found the uncertainty expressed by the advisory committee reviewing Dendreon’s Provenge to be a better guide for regulatory action than the panel’s numerical vote supporting approval, according to the FDA review documents for the first autologous cancer vaccine.
You may also be interested in...
US FDA’s Most Controversial Drug Approval Decisions, From A To Z
Following accelerated approval of Biogen’s Alzheimer’s drug aducanumab in the US, we look back at 10 of the FDA’s most controversial drug approval decisions, from Addyi to Zohydro.
US FDA’s Most Controversial Drug Approval Decisions, From A To Z
With action imminent on Biogen’s Alzheimer’s drug aducanumab, the Pink Sheet looks back at 10 of FDA’s most controversial drug approval decisions, from Addyi to Zohydro.
Accelerated Evolution Of Prostate Cancer Therapy Shaped Xtandi Review
Medivation/Astellas’ enzalutamide capped off an extraordinary three-year run in advanced castration-resistant prostate cancer therapy, with three successive NMEs each offering a greater survival advantage than the last. That accelerated evolution of new therapies created a complex context for FDA reviews.